Dermira, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 333
- Market Cap
- -
- Website
- http://www.dermira.com
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- Drug: Olumacostat Glasaretil Gel, 5.0%
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 748
- Registration Number
- NCT03127956
- Locations
- 🇺🇸
Rady Children's Hospital UCSD Pediatric and Adolescent Derm, San Diego, California, United States
🇺🇸University Clinical Trials Inc., San Diego, California, United States
🇺🇸Finlay Medical Research, Miami, Florida, United States
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- Drug: Olumacostat Glasaretil Gel, 5.0%Other: Olumacostat Glasaretil Gel, Vehicle
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 744
- Registration Number
- NCT03073486
- Locations
- 🇺🇸
Advanced Skincare Surgery & MedCenter, Fullerton, California, United States
🇨🇦Enverus Medical Research, Surrey, British Columbia, Canada
🇺🇸Synexus US, LP, dba, Research Across America, Dallas, Texas, United States
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- Drug: Olumacostat Glasaretil Gel, 5.0%Other: Olumacostat Glasaretil Gel, Vehicle
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 759
- Registration Number
- NCT03028363
- Locations
- 🇺🇸
Research Institute of the Southeast, LLC, West Palm Beach, Florida, United States
🇺🇸Rady Children's Hospital UCSD Pediatric and Adolescent Derm, San Diego, California, United States
🇺🇸University Clinical Trials Inc., San Diego, California, United States
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT02431052
- Locations
- 🇺🇸
T. Joseph Raoof, MD, Inc., Encino, California, United States
🇺🇸Skin Search of Rochester, Inc., Rochester, New York, United States
🇺🇸The Education & Research Foundation, Inc., Lynchburg, Virginia, United States
A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01993433
- Locations
- 🇨🇦
Clinique Médicale Dr Isabelle Delorme, Drummondville, Quebec, Canada
🇨🇦Innovaderm Research, Inc, Montreal, Quebec, Canada
A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT01993420
- Locations
- 🇨🇦
Clinique Médicale Dr Isabelle Delorme, Drummondville, Quebec, Canada
🇨🇦Innovaderm Research, Inc, Montreal, Quebec, Canada
A Safety and Efficacy Study of DRM02 in Subjects With Rosacea
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01993446
- Locations
- 🇨🇦
Windsor Clinical Research, Inc., Windsor, Ontario, Canada
🇨🇦Clinique Médicale Dr Isabelle Delorme, Drummondville, Quebec, Canada
🇨🇦Innovaderm Research, Inc, Montreal, Quebec, Canada
A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel
- Conditions
- Acne Vulgaris
- Interventions
- Drug: Olumacostat Glasaretil Gel, 7.5%Other: Olumacostat Glasaretil Gel, Vehicle
- First Posted Date
- 2013-09-06
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT01936324
- Locations
- 🇨🇦
Innovaderm Research, Inc, Montreal, Quebec, Canada
🇨🇦Centre de Recherche Dermetologique du Quebec Metropolitain (CRDQ), Quebec, Canada
🇨🇦K. Papp Clinical Research Inc., Waterloo, Ontario, Canada
Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers
- Conditions
- Acne Vulgaris
- Interventions
- Drug: Red Light (PDT)
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01830764
- Locations
- 🇺🇸
TKL Research Inc (Research Clinics Division), Paramus, New Jersey, United States
Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT01490736
- Locations
- 🇨🇦
Innovaderm Research, Inc, Montreal, Quebec, Canada